Beijing Huashi Tianfu Biopharmaceutical Technology

Beijing Huashi Tianfu Biopharmaceutical Technology is a Chinese biotechnology company focused on developing innovative therapies for oncology, with a specific emphasis on hepatocellular carcinoma (HCC). As a subsidiary of the Huashi Pharmaceutical Group, the company utilizes biomarker-driven strategies to advance its clinical pipeline, including a Phase 3 program for Interferon-alpha (IFN-alpha) in resected HCC patients with low miR-26 expression. Additionally, the company is conducting Phase 3 trials for K-001, a marine-derived biological product intended for the treatment of advanced HCC. Headquartered in Beijing, the company operates within the integrated R&D and clinical service ecosystem of its parent group to bring novel treatments to the Chinese market.